Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Urology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Bladder Carcinoma Clinical Trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (66) clinical trials

Enzalutamide for Bladder Cancer Chemoprevention

- A blood draw and an electrocardiogram (EKG). The blood draw will check levels of testosterone, dihydro-testosterone, estradiol, and Vitamin D. Pre-study blood-work will also include a complete blood count (CBC), basic metabolic panel (BMP/CHEM8) and liver function test (LFT) if any of these labs were not drawn within 1 ...

Phase

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

This is a single arm two-stage phase II study designed to evaluate the overall response rate in patients with metastatic urothelial cancer demonstrating c-MET or RON overexpression who have failed prior therapy with a cisplatin or carboplatin containing regimen. Immunohistochemistry will be utilized to define tumor sample c-MET and RON ...

Phase

Safety Study of MGD009 in B7-H3-expressing Tumors

This study is a Phase 1 open-label, dose escalation, cohort expansion, and efficacy follow-up study of MGD009 administered intravenously (IV) on an every-other-week schedule for up to one year (14 cycles). The dose escalation phase is designed to characterize the safety and tolerability of MGD009 and to define the maximum ...

Phase

Tisotumab Vedotin (HuMax -TF-ADC) Safety Study in Patients With Solid Tumors

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of tisotumab ...

Phase

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Primary Objective: - To analyse time to tumor progression in patients cystectomized for locally advanced TCC of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e. postoperative reduced renal function, advanced age). Patients are randomized to receive either adjuvant Gemcitabine immediately after radical operation (treatment arm A) or no ...

Phase